| 贺 芬,郑艳妮,沙海旺,袁伟伟,李玲霞.呼吸机辅助美罗培南及胸腺法新治疗重症肺炎的疗效及对患者血清炎症因子水平的影响[J].,2020,(21):4113-4116 |
| 呼吸机辅助美罗培南及胸腺法新治疗重症肺炎的疗效及对患者血清炎症因子水平的影响 |
| Efficacy of Ventilator-assisted Meropenem and Thymus Method in the Treatment of Severe Pneumonia and its Effect on the Serum Inflammatory Factors Levels |
| 投稿时间：2020-05-02 修订日期：2020-05-26 |
| DOI：10.13241/j.cnki.pmb.2020.21.025 |
| 中文关键词: 美罗培南 胸腺法 重症肺炎 炎症因子 |
| 英文关键词: Meropenem Thymus method Severe pneumonia Immune factor |
| 基金项目:国家自然科学基金项目（81760069）；陕西省社会发展科技攻关项目（2016SF-075） |
|
| 摘要点击次数: 688 |
| 全文下载次数: 577 |
| 中文摘要: |
| 摘要 目的：探讨呼吸机辅助美罗培南及胸腺法新治疗重症肺炎的临床疗效及血清炎症因子水平的影响。方法：选取2018年8月至2020年2月我院收治的96例重症肺炎患者作为研究对象，将其随机均分为两组。对照组48例给予美罗培南治疗，研究组48例给予呼吸机辅助美罗培南及胸腺法新治疗，观察和比较两组患者的疗效、肺部症状的改善情况、治疗前后血清白细胞介素(IL，Interleukin)-６、IL-10、肿瘤坏死因子(Tumor Necrosis Factor-α，TNF-α)水平的变化及不良反应的发生情况。结果：治疗后，研究组总有效率为97.96 %，显著高于对照组(85.41 %，P＜0.05)；研究组肺部啰音消失时间及炎症吸收时间明显短于对照组(P＜0.05)，IL-6、IL-10、TNF-α明显低于对照组(P<0.05)。治疗过程中，研究组不良反应率为2.08 %，显著低于对照组(31.25 %，P＜0.05)。结论：呼吸机辅助美罗培南及胸腺法新用于治疗重症肺炎患者的临床疗效明显优于单用美罗培南治疗，其能有效减轻炎症反应，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of ventilator-assisted meropenem and thymus therapy on severe pneumonia and the influence of immune factors. Methods: 96 patients with severe pneumonia admitted in our hospital from August 2018 to February 2020 were selected as the research object, and they were randomly divided into two groups, 48 cases in the control group and treated with meropenem. 48 cases in the study group, given ventilators Adjuvant meropenem and thymus method new treatment, observe the efficacy of the two groups of patients, the improvement of the lungs, IL-6, IL-10, TNF-α changes and the incidence of adverse reactions. Results: The total effective rate in the study group was 97.96 %, which was significantly higher than that in the control group (85.41 %, P<0.05). Compared with the improvement of the lungs in the two groups, the time for lung rales disappearance and inflammation absorption in the study group were significantly lower than those in the control group (P<0.05). There was no significant difference in IL-6, IL-10 and TNF-α between the two groups pre-treatment (P>0.05), after treatment, the study group was significantly lower than the control group (P<0.05). The adverse reaction rate in the study group was 2.08 %, significantly lower than the control group (31.25 %, P<0.05). Conclusion: The ventilator-assisted meropenem and thymus method were newly used to treat patients with severe pneumonia. They have good clinical efficacy, could improve the patient's body immunity, and had fewer adverse reactions. They were safe and reliable, and were worthy of clinical promotion and application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
